SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to SYRS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 19.64. This target is 282% above the current price.
SYRS was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about SYRS.
In the previous month the buy percentage consensus was at a similar level.
SYRS was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-10-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-05-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-03 | Oppenheimer | Maintains | Outperform |
| 2023-03-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-05 | Piper Sandler | Maintains | Overweight |
| 2022-11-15 | JMP Securities | Maintains | Market Outperform |
| 2022-11-15 | Oppenheimer | Maintains | Outperform |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-10 | Oppenheimer | Maintains | Outperform |
| 2022-07-12 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-17 | Alliance Global Partners | Maintains | Buy |
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-09-23 | Roth Capital | Maintains | Buy |